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OBJECTIVE: The aim of this study is to compare the effects of traditional nonsteroidal anti-inflammatory drugs with nonsteroidal
anti-inflammatory drugs that are selective cyclooxygenase-2 (COX-2) inhibitors in the process of bone regeneration in a rat
model.
MATERIALS AND METHODS: Forty-four Wistar strain rats were subjected to osteotomy of the right femur and randomly
divided into 3 groups according to the drug to be given (diclofenac, rofecoxib, or placebo). Each group was divided into 2
subgroups according to the time to euthanasia after the surgery. The animals of Subgroup 1 were submitted to euthanasia 2 weeks
after surgery, and those of Subgroup 2, underwent euthanasia 4 weeks after surgery. Radiographic examinations and bone callus
histomorphometry were analyzed.
RESULTS: No intergroup statistical difference was found in the bone callus area or in bone formation area 2 and 4 weeks after
surgery. Intra-group analysis concerning the bone neoformation area inside the callus showed a significant difference within the
diclofenac group, which presented less tissue.
CONCLUSIONS: Fracture consolidation in Wistar rats occurs within less than 2 weeks, and the use of nonsteroidal anti-
inflammatory drugs does not significantly influence this process.
KEYWORDS: Anti-inflammatory agents, nonsteroidal. Bone regeneration. Fracture consolidation. Rats, Wistar. Osteotomy.
INTRODUCTION
Prostaglandins (PGs) are local, autacoid hormones
formed by the oxygenation of arachidonic acid (AA) from
cell membranes from which it is removed by phospholipase
A2 (PLA2). Prostaglandins are produced by cyclooxygenase
(COX), an enzyme also known as prostaglandin H2 synthase
(PGHS). Cyclooxygenase is responsible for 2 reactions in-
volving AA: the first reaction converts AA into the highly
unstable Prostaglandin G2, and the second converts Prostag-
landin G2 into Prostaglandin H2. Each tissue metabolizes
Prostaglandin H2 in a different manner according to the en-
zymes in it, generating different active metabolites of this
substance. Although they are better known for their effects
as mediators of inflammatory processes, Prostaglandins play
an important role in other physiological processes, such as
protection of the gastric mucosa, activation of the platelet
system, and regulation of renal blood flow, in addition to
acting as neurotransmitters.1–10
Until recently it was thought that the AA concentration,
and therefore the action of phospholipase A2, was the lim-
iting factor for the production of PGs.11 It is now known
that the limiting stage is the one mediated by COX.
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At first it was thought that only 1 type of COX existed.
It was only in the beginning of the 1990s that studies in
cells of rat ovaries12 produced the first evidence for a sec-
ond isoform of COX. At the same time, the conclusion was
reached that the already known isoform, now called
cyclooxygenase-l (COX-1), is constitutive, meaning that it
can be found regularly in tissues, while the other isoform,
called cyclooxygenase-2 (COX-2), is expressed only
through signaling.13 Finally in 1992the COX-2 gene was
cloned.14
The fact that COX-1 is expressed constitutively while
COX-2 is expressed in events such as inflammation suggests
a more physiologic role for the first enzyme, while COX-2
would be more important in the production of PGs in patho-
logical processes. Because of this, the benefit of using drugs
that selectively inhibit COX-2, thus preventing frequent gas-
tric disorders (such as ulcers), and changes in the coagula-
tion mechanism, nephrotoxicity—all adverse reactions that
prevent prolonged use of traditional nonsteroidal anti-inflam-
matory drugs (NSAIDs), which inhibit the activity of both
COX-1 and COX-2—can be clearly seen.15–19
However, it is known that COX-2 is not involved only
in inflammatory processes. It is also important in a series
of physiological processes such as child birth labor, when
it acts by promoting mechanisms that facilitate uterine con-
tractions.9,15
Prostaglandins play an important role in bone metabo-
lism. Recent studies have shown that in COX-2 knockout
mice compared to COX-1 knockout mice, there is also a
decrease in bone resorption in response to parathyroid hor-
mone (PTH).20 In cultures of human cells, it has been shown
that PTH is responsible for an increase in COX-2 expres-
sion and, consequently, of PGs in bone tissue.10
At lower concentrations,10 PGs seem to have an effect
on the formation of bone tissue.21,22 Studies have shown that
the production of lamellar bone induced by mechanical
stress is mediated by COX-2.23,24
It is increasingly believed that PGs are important in
bone repair, since tissue levels of PGs increase between Day
3 and Day 14 after fracture in rabbit tibias.25
Fracture consolidation is a complex process involving
intramembranous bone formation and direct differentiation
of mesenchymal cells into osteoblasts, as well as endochon-
dral ossification, when the bone matrix is deposited onto
cartilage.
A study that used COX-2 knockout mice showed that
both types of ossification are impaired by the absence of
this enzyme. The most striking point in this study was the
persistence of mesenchymal cells in the site of the frac-
ture,26 pointing to an important role of PGs in the differ-
entiation of these cells into osteoblasts. The study also
pointed to a possible role of PGs in the recruiting of mes-
enchymal cells as well as in remodeling of the bone scar
or callus.
Based on these experimental findings and because of
the use of selective COX-2 inhibitors in medical practice,
it is important to study their effects of on the process of
bone regeneration.
OBJECTIVE
The objective of this study is to compare the effects of
using traditional nonsteroidal anti-inflammatory drugs
(NSAIDs) and NSAIDs that are selective COX-2 inhibitors
in the process of bone regeneration in a rat model. We
analyzed radiographic findings and histomorphometric data
of the callus related with the time to regeneration of the
fracture and bone neoformation area inside the callus.
MATERIAL AND METHODS
Forty-four Wistar strain rats weighing 341 ± 31 grams
(mean ± SD) were used for this study. The rats were kept
in controlled conditions of temperature and lighting and
with no restriction on food or water. All rats were submit-
ted to an osteotomy of the right femur with a mechanical
saw and osteotome. The rats were then randomly divided
into 3 groups (1, 2, and 3) according to the drug to be given.
Each group was divided into 2 subgroups according to the
time to euthanasia after the surgery: Subgroup 1 2 weeks
(14 days) after the surgery and Subgroup 2 4 weeks (28
days) after the surgery as follows: placebo (P), P.1 Group
2 weeks and P.2 Group 4 weeks; diclofenac (D) D.1 Group
2 weeks and D.2 Group 4 weeks; and rofecoxib (R), R.1
Group 2 weeks and R.2 Group 4 weeks.
Thirteen animals were not included in the study: 9 due
to infection and 4 due to bone fixation failure (Kirschner
wire migration). All groups included 5 rats each, except
for the R.1 Group, which included 6 animals.
The rats in the P groups received orally 1.25 mL/kg of
a solution made of 2 parts of condensed milk and 1 part
of water, once daily, at the same time every day. The ani-
mals in the D groups received a similar solution of 3 mg/
kg diclofenac sodium (a nonselective COX inhibitor), while
the rats in the R groups received rofecoxib (a selective
COX-2 inhibitor) at a dose equivalent to 1 mg/kg. These
dosages were selected based in experimental and clinical
studies. 9,10,15-17 The animals were weighed once a week for
drug dose adjustment.
Fracture. All animals were anesthetized using thiopen-
tal and ketalar. The right hind limb of each rat was pre-
pared for surgical procedure. After assembling the surgi-
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cal table in a laminar air flow environment, the animal was
positioned, and a 2% iodine solution was first used exter-
nally as an antiseptic.
A 2.5-cm incision was made along the femoral diaphy-
sis. The subcutaneous and muscular planes were incised
until the bone plane was reached.
The femur was exposed, a small mechanical saw was
used to weaken the cortical bone layer (Figure 1), and an
osteotome was used to finish the osteotomy (Figure 2).
Intramedullary bone fixation was performed using a 1.25-
mm diameter Kirschner wire and an electric drill (Figures 3
and 4). The wound was closed using 4-0 nylon sutures.
The animals of Subgroups 1 (P.1, D.1, and R.1) were
subjected to radiologic examination 15 days after oste-
otomy and 30 minutes prior to euthanasia. The animals of
Subgroups 2 (P.2, D.2, and R.2) underwent a radiologic ex-
amination 2 and 4 weeks after osteotomy; the second exam
was performed 30 minutes prior to euthanasia. Radiographs
were taken to enable the analysis of bone union in the frac-
ture area. Each radiograph was evaluated independently by
2 orthopedists blinded to the procedure.
After euthanasia, the femur was extracted without re-
moving the Kirschner wire, placed in a glass container with
approximately 100 mL of a 10% formol solution, and sent
for histomorphometric analysis of the bone callus. A sin-
gle pathologist experienced in bone tissue analysis per-
formed the anatomical and pathological assessment. This
histomorphometric assessment was blinded and measured
the bone callus area and the neoformation areas inside the
callus in square micrometers (Carl Zeiss AxioVision soft-
ware).
The statistical analysis of the callus area and the bone neo-
formation area inside the callus among the 2-week subgroups
(P.1 vs D.1 vs R.1) and among the 4-week subgroups (P.2 vs
D.2 vs R.2) was performed using the nonparametric Kruskall-
Wallis and Dunn tests. For intragroup analysis (P.1 vs P.2; D.1
vs D.2; R.1; R.2), the Mann-Whitney test was used. We con-
sidered P < 0.05 to indicate a statistically significant differ-
ence. The total area, by individual animal, of the bone callus
area and of the bone neoformation area inside the callus for
each group is listed in Tables 5,6,7, and 8.
Figure 2 - End of the femur osteotomy with manual saw
Figure 1 - Femur osteotomy with manual saw
Figure 4 - Internal fixation of the femur with intramedullary nail
Figure 3 - Intramedullary nail fixation of the femur
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RESULTS
Radiological examination. The orthopedists had diffi-
culty in analyzing the X-rays. When asked to evaluate con-
solidation, quality of consolidation, and mechanical
strength of the callus, they could only define whether con-
solidation was present or not. Both considered that all ani-
mals presented radiographic signs of consolidation in the
examinations performed at 2 and 4 weeks after osteotomy.
Histomorphometric examination. In the Subgroup 1 (eu-
thanasia at 2 weeks after osteotomy) no statistical differ-
ence was found concerning the bone callus area (Figure 5)
or the bone neoformation area inside the callus P = 0.838
and P = 0.366, which was confirmed by the Dunn test (Ta-
bles 1 and 3, Figure 6). In the Subgroup 2 (euthanasia at 4
weeks) there was no statistical difference in the bone cal-
lus area or in the bone neoformation area inside the callus
(P = 0.9254 and P = 0.858, respectively (Tables 1 and 3).
No significant intragroup difference was found regard-
ing the amount of callus formation (Table 2). The intra-
group analysis of the amount of bone neoformation area
inside the callus showed a significant difference within the
diclofenac group only (Table 4), which had less organized
bone tissue.
DISCUSSION
The radiographic examination proved to be very diffi-
cult to analyze, possibly because no comparison parameter
was adopted. Since the orthopedists felt comfortable only
to define presence of consolidation or absence of union of
fragments, the radiograph examinations were useful for
Table 3 - Intergroup comparison of bone neoformation area
among the groups with at 4 and 2 weeks after osteotomy
placebo vs rofecoxib Bone Neoformation Area Data
vs diclofenac (Kruskall-Wallis and Dunn’s Test)
(4 weeks) (2 weeks)
global p = 0.858 0.366
global P = 0.858 P = 0.366
placebo vs rofecoxib P > 0.05 P > 0.05
placebo vs diclofenac P > 0.05 P > 0.05
rofecoxib vs diclofenac P > 0.05 P > 0.05
Table 2 - Intragroup comparison of bone callus area related
to the time of sacrifice (2 vs 4 weeks after osteotomy)
2 weeks vs 4 weeks Bone Callus Area Data
(Mann-Whitney U Test)
two-tailed One-tailed
P (2-tailed) P (1-tailed)
Placebo (n = 5) 1.000 0.5
Rofecoxib (n = 5) 0.7922 0.3961
Diclofenac (n = 5) 0.6905 0.34525
Table 1 - Intergroup comparison of bone callus area among
the groups withat 4 and 2 weeks after osteotomy
placebo vs rofecoxib Bone Callus Area Data
vs diclofenac (Kruskall-Wallis and Dunn’s Test)
(4 weeks) (2 weeks)
global p = 0.9254 0.838
global P = 0.9254 P = 0.838
placebo vs rofecoxib p > 0.05 P > 0.05
placebo vs rofecoxib P > 0.05 P > 0.05
placebo vs diclofenac p > 0.05 P > 0.05
placebo vs diclofenac P > 0.05 P > 0.05
rofecoxib vs diclofenac p > 0.05 P > 0.05
rofecoxib vs diclofenac P > 0.05 P > 0.05
Figure 6 - Bone neoformation (blue)Figure 5 - Bone callus (red)
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documentation purposes only. The relative stabilization
obtained with the intramedullary fixation with no immo-
bilization should have resulted in a large amount of cal-
lus, but at the end of the fourth week after osteotomy, we
observed bone consolidation with no hypertrophic callus
(Figure 7). Probably, a large bone callus would be seen later
in this experimental model.21,24
Table 8 - Total area (µm²) ofAbsolute Values of bone
neoformation, by animal, area of the groups with at 2 weeks
after osteotomy
pPlaceboo 2 weeks rofecoxib 2 weeks diclofenac 2 weeks
(µm²) (µm²) (µm²)
7319587.63 3866949.2 3627909.45
2030648.85 7633471.25 12852508.24
26380765.76 4268346.8 118609787.6
23812705.93 4435367.74 11641659.58
1281206.82 8305930.49 21485173.75
8396761.08
Table 7 - Total area (µm²) ofAbsolute Values of bone
neoformation, by animal, area of the groups with 4 weeks
after osteotomy
placebo 4 weeks rofecoxib 4 weeks diclofenac 4 weeks
(µm²) (µm²) (µm²)
2282761.19 4857981.71 12273142.74
9033146.46 7387806.89 1519290.04
4730112.13 8147412.04 10951987.46
5769356.47 1668854.29 6712868
6447815.92 9888789.98 3212695.29
Table 6 - Total area (µm²)Absolute Values of bone callus,
by animal, area of the groups at 2 weeks after osteotomy
with 2 weeks
placebo 2 weeks rofecoxib 2 weeks Diclofenacdiclofenac
(µm²) (µm²) 2 weeks (µm²)
13233300.56 7197071.96 9320039.32
2446102.14 25604527.57 830794811.6
851674992.8 8652712.83 10476857.27
23812705.93 24555917.21 22604846.42
11895233.29 14904464.09 51861063.88
14013271.87
Table 5 - Absolute ValuesTotal area (µm²) of bone callus,
by animal, area of the groups awith t 4 weeks after osteotomy
placebo 4 weeks rofecoxib 4 weeks diclofenac 4 weeks
(µm²) (µm²) (µm²)
6641938.57 10567408.86 38890450.63
20682657.56 19344045.59 7227083.11
14712615.58 27383555.64 137919396.1
19421364.88 8211871.61 16307445
14792818.05 17969138.59 9890636.63
Table 4 - Intragroup comparison of bone neoformation area
related to the time of sacrifice (2 vs 4 weeks after osteotomy)
2 weeks vs 4 weeks Bone Neoformation Area Data
(Mann-Whitney U Test)
two-tailed One-tailed
P (2-tailed) P (1-tailed)
Placebo 0.8413 0.42065
Rofecoxib 0.9307 0.46535
Diclofenac 0.0952 0.0476
Figure 7 - Radiographic image of femur consolidation
Regarding the callus area, the histomorphometric analy-
sis showed no differences between subgroups (P.1 vs D.1
vs R.1 and P.2 vs D.2 vs R.2) at either 2 weeks or 4 weeks
after osteotomy. This led us to believe that the administra-
tion of selective or nonselective non steroidal anti-inflam-
matory agents does not interfere with bone regeneration
measured as the amount of callus formation in Wistar rats.
Despite the findings of other clinical and experimental stud-
ies,21–26 this model demonstrated that the administration of
usually recommended doses of selective or nonselective non
steroidal anti-inflammatory agents does not interfere in the
ossification after bone osteotomy in the Wistar rat.
Analyzing the amount of callus formation, we did not find
intragroup differences in comparing subgroups 1 and 2 (eu-
thanasia 2 weeks and 4 weeks after osteotomy). In this model
bone regeneration after bone osteotomy occurs in 2 weeks.
Concerning the comparison between the intragroup bone
neoformation areas (organized bone tissue inside the bone
callus), we found a significant difference within the
diclofenac (D) group, since the average area of the 4-week
group (subgroup 2) was smaller than that of the 2-week group
(subgroup 1). It is possible that simultaneous inhibition of
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COX-1 and COX-2 may explain this phenomenon, but fur-
ther research should be undertaken to explain this finding.
CONCLUSIONS
Bone consolidation in Wistar rats occurs by 2 weeks
after osteotomy, and the use of selective or nonselective
nonsteroidal anti-inflammatory drugs does not interfere in
the amount of callus formation between 2 and 4 weeks af-
ter the osteotomy. The inhibition of COX-1 and COX-2
may restrain the production of well-organized bone neo-
formation areas inside the callus.
RESUMO
Tiseo BC, Namur GN, de Paula EJL, Mattar Junior R, de
Oliveira CRGCM. Estudo experimental da ação dos anti-
inflamatórios não hormonais inibidores seletivos da
ciclooxigenase 2 (COX-2) e anti-inflamatórios tradicionais
na regeneração óssea. Clinics. 2006;61(3):223-30.
OBJETIVO: Comparar os efeitos do uso de antiinfla-
matórios não-esteróides tradicionais (AINES) e AINES que
são inibidores seletivos da ciclooxigenase-2 (COX-2), no
processo de regeneração óssea em ratos.
MATERIAL E MÉTODO: Quarenta e quatro ratos da li-
nhagem Wistar submetidos a osteotomia do femur direito e
divididos em três grupos, conforme o medicamento que re-
ceberam (diclofenaco, rofecoxib e placebo). Cada grupo foi
dividido em dois subgrupos, conforme o tempo até o sacri-
fício, após a cirurgia. Os animais do subgrupo 1 foram sa-
crificados duas semanas após a cirurgia e os do subgrupo 2,
quatro semanas após a cirurgia. Foram analisados exames
radiográficos e a histomorfometria do calo ósseo.
RESULTADOS: Não foram encontradas diferenças esta-
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tísticas na área do calo ósseo 2 e 4 semanas após a cirur-
gia. No que se refere à área de neoformação óssea dentro
do calo, observou-se diferença estatisticamente significante
apenas dentro do grupo do diclofenaco, que apresentou
menos tecido.
CONCLUSÕES: A consolidação da fratura em ratos Wistar
ocorre dentro de 2 semanas e o uso de antiinflamatórios não-
esteróides não influi de forma significante neste processo.
UNITERMOS: Antiinflamatórios não esteróides. Regene-
ração óssea. Consolidação da fratura. Ratos Wistar.
Osteotomia.
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